TrialEuropean journal of cancer (Oxford, England : 1990)2017

Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).

Sibylle Loibl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.